IJGC Podcast – Details, episodes & analysis

Podcast details

Technical and general information from the podcast's RSS feed.

IJGC Podcast

BMJ Group

Health & Fitness

Frequency: 1 episode/6d. Total Eps: 384

The International Journal of Gynecological Cancer (IJGC) podcast explores the latest research on detection, prevention, diagnosis, and treatment of gynecologic malignancies. Enjoy interviews with leading experts as they discuss novel and relevant topics in the field of gynecologic cancer. Join Editor-in-Chief Dr. Pedro Ramirez and his guests for an interactive and educational experience. Subscribe now or listen on your favourite podcast platform. IJGC - ijgc.bmj.com - is the official journal of the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology.

Read moreCollapse

Site

RSS

Apple

Recent rankings

Latest chart positions across Apple Podcasts and Spotify rankings.

Apple Podcasts

🇫🇷 France - medicine
22/01/2026
#94
🇫🇷 France - medicine
21/01/2026
#67
🇬🇧 Great Britain - medicine
19/10/2025
#95
🇬🇧 Great Britain - medicine
30/07/2025
#100
🇨🇦 Canada - medicine
13/04/2025
#71
🇨🇦 Canada - medicine
18/01/2025
#87
🇨🇦 Canada - medicine
17/01/2025
#87
🇬🇧 Great Britain - medicine
10/01/2025
#85

Spotify

No recent rankings available

Shared links between episodes and podcasts

Links found in episode descriptions and other podcasts that share them.

See all

https://soundcloud.com/bmjpodcasts/the-importance-and-clinical-relevance-of-classifications-in-cervical-adenocarcinoma?in=bmjpodcasts/sets/ijgc-podcast
1 share

RSS feed quality and score

Technical evaluation of the podcast's RSS feed quality and structure.

See all

RSS feed quality

To improve

Score global : 32%

Publication history

Monthly episode publishing history over the past years.

Year

Latest published episodes

Recent episodes with titles, durations, and descriptions.

See all

Secondary Cytoreductive Surgery in Endometrial Cancer with Francesco Fanfani

Monday, November 25, 2024 • Duration 33:36

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Francesco Fanfani to discuss secondary cytoreductive surgery in endometrial cancer. Dr. Francesco Fanfani serves as an associate professor in gynecologic oncology at Fondazione Policlinico Universitario Agostino Gemelli, IRCCS in Rome, Italy.

Highlights:

Secondary cytoreductive surgery with complete gross resection, has the potential to offer significant survival benefits in recurrent endometrial cancer patients.
Age <65 years, single site recurrence, and nodal or hematogenous recurrence as predictive factors for complete cytoreduction.
The study’s findings could influence the decision making process in treatment selection, offering valuable insights for future prospective studies and potential impacts on research and clinical practice.

Read moreCollapse

KEYNOTE-A18 Overall Survival Results: Pembrolizumab and Chemoradiotherapy with Domenica Lorusso

Monday, November 18, 2024 • Duration 32:27

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Domenica Lorusso to discuss KEYNOTE-A18 Overall Survival Results: Pembrolizumab and Chemoradiotherapy. Dr. Domenica Lorusso, MD, PhD, directs the Gynaecological Oncology Unit at Humanitas Hospital, Milan, and holds a Full Professorship in Obstetrics and Gynaecology at Humanitas University, Rozzano, Milan. She has led/participated in approximately 250 phase I-IV clinical trials. Currently overseeing more than 60 studies as Principal Investigator, Dr. Lorusso also chairs the Clinical Trials Committee of the MITO Group. She serves on the Board of Directors of the GCIG and is an active member of ENGOT, where she chairs the Gynecological Cancer Academy. Additionally, she sits on the Board of Directors of the ESGO. With around 300 international oncology publications and contributions to national and international treatment guidelines, her primary objectives are to ensure optimal patient care, foster clinical research, and advance international collaborations and education in the field.

Highlights:

In a phase 3 trial (ENGOT-cx11/GOG-3047/KEYNOTE-A18), pembrolizumab added to chemoradiotherapy significantly improved progression-free survival and overall survival for patients with locally advanced, high-risk cervical cancer.
Patient Group: 1060 patients with FIGO 2014 stage IB2–IVA cervical cancer from 30 countries were randomized to receive pembrolizumab with chemoradiotherapy or placebo with chemoradiotherapy.
Overall Survival: At a median follow-up of 29.9 months, the 36-month overall survival rate was 82.6% in the pembrolizumab group versus 74.8% in the placebo group, with a hazard ratio for death of 0.67 (95% CI 0.50–0.90; p=0.0040).
Safety Profile: Grade 3 or higher adverse events were reported in 78% of pembrolizumab-treated patients versus 70% in the placebo group, with higher rates of potentially immune-mediated adverse events in the pembrolizumab group (39% vs. 17%).
Conclusion: These findings confirm pembrolizumab plus chemoradiotherapy as an effective and potentially new standard of care for locally advanced cervical cancer.

Read moreCollapse

ERAS Guidelines and Outcomes Meta-analysis with Dr. Gregg Nelson

Monday, September 16, 2024 • Duration 37:11

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Gregg Nelson to discuss ERAS Guidelines and Outcomes Meta-analysis. Dr. Gregg Nelson is Professor and Chair of Gynecologic Oncology at the University of Calgary, in Calgary, Canada. He is the Physician Lead for ERAS Alberta and is Co-Chair of Enhanced Recovery Canada.

Highlights:

- Largest meta-analysis of ERAS randomized clinical trials finds hospital length of stay decreased by 1.9 days overall and risk of complications decreased by 29%, in favor of ERAS
- ERAS can be applied to both open and minimally invasive surgery
- ERAS benefits multiple surgery types

Read moreCollapse

SCCAN Study: Hospital Volume and Radical Hysterectomy

Saturday, March 11, 2023 • Duration 34:38

In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Dr. Nicolò Bizzarri to discuss the SCCAN study. Dr. Bizzarri is a former IJGC Editorial Fellow under the mentorship of Prof. Pedro Ramirez. He is a Gynecologic Oncologist at Policlinico Agostino Gemelli in Rome, president of the European Network of Young Gynecologic Oncologists (ENYGO), and he happily serves on the IJGC Early Career Editorial Board. Highlights: - Women with early-stage cervical cancer treated with primary radical hysterectomy had improved disease free survival if treated in hospitals with a higher number of radical hysterectomies per year. - Surgical volume of centers represented an independent prognostic factor affecting disease-free survival.

- Increasing number of radical hysterectomies performed in each center every year was associated with improved disease-free survival.

Read moreCollapse

Special Issue: Novel Therapies Leading to a New Landscape in Gynecologic Tumors

Friday, March 3, 2023 • Duration 35:11

In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Drs. Ainhoa Madariaga and Robert Coleman, two of the Guest Editors for this month’s special issue entitled “Novel Therapies Leading to a New Landscape in Gynecologic Tumors”. Dr. Madariaga is a Medical Oncologist in the Gynecologic Cancer Unit at 12 de Octubre University Hospital in Madrid, Spain. She is the chair of the Young and Early Career Investigator - EORTC Gynecological Cancer Group. Her research interests include patient reported outcomes and drug development. Dr. Coleman is a Gynecologic Oncologist and Chief Medical Officer at Sarah Cannon Research Institute (SCRI) in Nashville, TN. His research interests include drug development, clinical trial design and global medical education in gynecologic oncology. Highlights: - The alignment of cancer biology and novel treatment approaches are significantly extending the lives of patients with gynecologic malignancies, particularly with agents such as antibody drug conjugates, immunotherapy, and targeted agents. - The evolving therapeutic landscape is escalating the need for a clearer understanding of how precision medicine can most efficiently be implemented. - Emergence of drug resistance provides new challenges and opportunities through creative and strategic investigation of novel treatment and combinations. - Advances in testing platforms in bringing genomic testing to the global audience.

- Clinical trial interpretation requires critical evaluation of analytical primary and hypothesis-generating secondary endpoints – strategies to make appropriate inference is key to clinical trial design.

Read moreCollapse

Mentor’s Podcast: Robert Coleman

Friday, February 24, 2023 • Duration 22:57

In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Dr. Robert Coleman. Dr. Coleman is a Gynecologic Oncologist and Chief Medical Officer at Sarah Cannon Research Institute (SCRI) in Nashville, TN. His research interests include drug development, clinical trial design and global medical education in gynecologic oncology. Highlights: - Strong mentorship is vital to personal and academic development. However, it is a two-way street. True synergy will come from bilateral engagement. - Remember your clinic is your “laboratory” – keep a keen eye for clinical relationships, build hypotheses, and practice the exercise of how to best test it. Even in resource-constrained situations, the process of discovery and hypothesis testing will arm one to be a better investigator and to most appropriately interrogate the literature.

- A strong balance between personal and professional responsibilities will provide the environment for sustainability – this is the long game!

Read moreCollapse

Updates on Germ Cell Tumors with David Gershenson

Tuesday, February 14, 2023 • Duration 44:11

In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Dr. David M. Gershenson to discuss updates on germ cell tumors. Dr. Gershenson is Professor and former Chair of the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center. His major focus is on the clinical and translational research or rare ovarian cancers. Highlights: - The treatment of malignant ovarian germ cell tumor has evolved over the last 5 decades to represent one of our most remarkable success stories, with cure in 95+% of patients with stage I/II and approximately 75% of patients with stage III/IV. - AGCT1531 is a very important trial, which, if positive, will reduce toxicity by extending surveillance to patients with stage IA or IB malignant ovarian germ cell tumors, including grade 2 and 3 immature teratomas, yolk sac tumors, and non-gestational choriocarcinomas and will result in the substitution of carboplatin for cisplatin in the regimen for treatment of stage IC-III. - Fertility-sparing surgery is possible in the majority of young patients with malignant ovarian germ cell tumor, related to the following: a) 95% are confined to one ovary ; b) approximately 2/3s are stage I; and c) most patients are in their teenage years, 20s, and 30s and have not completed childbearing. - Major controversies differentiating the treatment of children and adults by pediatric oncologists/pediatric surgeons and gynecologic oncologists, respectively, include the extent of surgical staging and the role of postoperative chemotherapy in patients with pure immature teratoma. - For patients with malignant ovarian germ cell tumors who recur following primary therapy, BEP is recommended for those who have been treated with surgery alone. For those who have previously received BEP, standard management generally includes high-dose chemotherapy with stem cell rescue.

- Aspects of management of malignant ovarian germ cell tumors that require further study include the role of neoadjuvant chemotherapy and the role of secondary cytoreductive surgery.

Read moreCollapse

Molecular Classification and Risk Stratification Endometrial Cancer

Monday, February 6, 2023 • Duration 36:07

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. Jenny Mueller and Bill Zammarrelli to discuss molecular classification and risk stratification in endometrial cancer. Jenny Mueller, MD, is a gynecologic oncologist and assistant attending in the department of surgery at Memorial Sloan Kettering Cancer Center. She leads the endometrial cancer research team at MSKCC with an emphasis on prospective, translational, and collaborative efforts within and across institutions. Bill Zammarrelli, MD, currently works as a gynecologic oncology fellow at Memorial Sloan Kettering Cancer Center. He is a commissioned officer in the US Army and completed his residency at Walter Reed National Military Medical Center. His current research focuses on the genetics of endometrial cancer. Highlights: - PORTEC-1 and GOG-99 risk classifications are discordant for stage I grade 3 endometrioid endometrial carcinoma (EEC). - Stage I grade 3 EECs of CN-high molecular subtype have a worse 3-year progression-free survival compared to non-CN-high molecular subtypes.

- Molecular classification in combination with clinicopathologic factors may provide improved prognostic information.

Read moreCollapse

MIS in Recurrent Ovarian Cancer

Friday, February 3, 2023 • Duration 36:06

In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Professor Giovanni Scambia and Dr. Carmine Conte to discuss mildly invasive surgery in ovarian cancer. Prof. Scambia is the Director of the Gynecologic Oncology Unit and the Scientific Director of Fondazione Policlinico Universitario Agostino Gemelli IRCCS in Rome, Italy. He is Full Professor of Obstetrics and Gynaecology, at Catholic University in Rome, and Member of Consiglio Superiore di Sanità, Ministry of Health Italy and Vice President 1st Section of Consiglio Superiore di Sanità. He is President Elect of E.S.G.E. (European Society for Gynaecological Endoscopy), and Past President of the Italian Society of Obstetrics and Gynecology (S.I.G.O.). Prof. Scambia is specialized in gynaecological cancer treatment and research. He has studied and developed innovative surgical approaches for the cure of gynecological cancers and has been invited professor in several academic hospitals both in Europe and outside Europe, and he is considered an opinion leader in the field of gynecologic oncology. Dr. Carmine Conte works at the Gynecologic Oncology Unit at Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome, Italy. He got the ESGO Fellowship diploma and is recognized as a certified European Gynaecological Oncologist. Dr. Conte is a surgeon and researcher with special interest in minimally invasive surgery (laparoscopy and robotic) to treat cancerous and noncancerous diseases of the female reproductive system. Highlights: - The patients with oligometastatic recurrent disease had a higher likelihood of minimally invasive secondary cytoreductive surgery. - Lymphnodal recurrences can be easily approached by MIS. - Propensity-matched analysis showed no differences in survival between the MIS and open groups, with a higher rate of overall and severe early complications in the open group. - Diagnostic laparoscopy and PET/CT scan should be considered complementary because of the potential of each one to identify a different disease setting.

- A diagnostic laparoscopy before secondary cytoreductive surgery may prevent unnecessary laparotomies.

Read moreCollapse

Reviewing the January Issue with Andrea Rosati and Anisa Mburu

Wednesday, January 25, 2023 • Duration 24:47

In this episode of the IJGC Podcast, Editorial Fellows Andrea Rosati and Anisa Mburu discuss the contents of the January issue of IJGC.

IJGC Podcast – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

RSS feed quality and score

Publication history

Latest published episodes

Related Shows Based on Content Similarities

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

IJGC Podcast – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

Other24

SoundCloud1

RSS feed quality and score

Publication history

Latest published episodes

Similar podcasts and content

Related Shows Based on Content Similarities

Related Shows Based on Content Similarities

Other24

SoundCloud1

Apple Podcasts

Spotify